Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.
Int J Clin Oncol. 2023 Jul;28(7):893-900. doi: 10.1007/s10147-023-02338-6. Epub 2023 Apr 18.
The Geriatric Nutritional Risk Index (GNRI) is a nutritional index for elderly patients that is associated with prognosis in cancer patients. We investigated using the GNRI in patients with metastatic colorectal cancer to predict prognosis.
This study included 419 metastatic colorectal cancer patients who received first-line chemotherapy between February 2005 and December 2020. First, we calculated pre-treatment GNRI and divided the patients into four groups according to the values (G1-G4). We evaluated patient characteristics and overall survival in the four groups.
Overall, 419 patients were included. The median follow-up was 34.4 months. Lower GNRI was positively associated with a lower grade Eastern Cooperative Oncology Group Performance Status (p = 0.009), synchronous metastases (p < 0.001), primary tumor resection prior to chemotherapy (p = 0.006), and did not undergo resection after chemotherapy (p < 0.001). Patients with low GNRI had significantly shorter overall survival than the group with high GNRI (median OS: G1 = 19.3 months [M], G2 = 30.8 M, G3 = 38 M, G4 = 39.7 M; log-rank test, p < 0.001). Multivariate Cox regression analysis showed that GNRI was an independent prognostic factor (G3: HR = 0.49, 95% CI = 0.35-0.69; G4: HR = 0.67, 95% CI = 0.48-0.93). In the subgroup analysis of overall survival, we found no interaction between clinicopathological factors and the prognostic value of GNRI. Interestingly, younger patients (< 70 years) but not older patients showed a significant difference in overall survival according to GNRI, despite being the metric being designed for elderly patients.
Pretreatment GNRI can be a prognostic marker for patients with mCRC who received systemic chemotherapy.
老年营养风险指数(GNRI)是一种针对老年患者的营养指数,与癌症患者的预后相关。我们在转移性结直肠癌患者中使用 GNRI 来预测预后。
本研究纳入了 2005 年 2 月至 2020 年 12 月期间接受一线化疗的 419 例转移性结直肠癌患者。首先,我们计算了治疗前的 GNRI,并根据 GNRI 值将患者分为 4 组(G1-G4)。我们评估了 4 组患者的特征和总生存情况。
共纳入 419 例患者。中位随访时间为 34.4 个月。较低的 GNRI 与较低的东部肿瘤协作组体力状态评分(ECOG PS)(p=0.009)、同步转移(p<0.001)、化疗前原发肿瘤切除(p=0.006)和化疗后未行切除(p<0.001)相关。低 GNRI 组的总生存时间明显短于高 GNRI 组(中位 OS:G1=19.3 个月[M],G2=30.8 个月[M],G3=38 个月[M],G4=39.7 个月[M];log-rank 检验,p<0.001)。多因素 Cox 回归分析显示,GNRI 是独立的预后因素(G3:HR=0.49,95%CI=0.35-0.69;G4:HR=0.67,95%CI=0.48-0.93)。在总生存的亚组分析中,我们未发现临床病理因素与 GNRI 预后价值之间存在交互作用。有趣的是,尽管 GNRI 是为老年患者设计的,但年轻患者(<70 岁)而非老年患者的总生存情况根据 GNRI 有显著差异。
治疗前 GNRI 可作为接受全身化疗的转移性结直肠癌患者的预后标志物。